JP2023107883A5 - - Google Patents

Download PDF

Info

Publication number
JP2023107883A5
JP2023107883A5 JP2023096692A JP2023096692A JP2023107883A5 JP 2023107883 A5 JP2023107883 A5 JP 2023107883A5 JP 2023096692 A JP2023096692 A JP 2023096692A JP 2023096692 A JP2023096692 A JP 2023096692A JP 2023107883 A5 JP2023107883 A5 JP 2023107883A5
Authority
JP
Japan
Prior art keywords
patient
composition
surgery
glp
parenteral nutrition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023096692A
Other languages
English (en)
Japanese (ja)
Other versions
JP7752152B2 (ja
JP2023107883A (ja
Filing date
Publication date
Priority claimed from JP2020526107A external-priority patent/JP7296958B2/ja
Application filed filed Critical
Publication of JP2023107883A publication Critical patent/JP2023107883A/ja
Publication of JP2023107883A5 publication Critical patent/JP2023107883A5/ja
Application granted granted Critical
Publication of JP7752152B2 publication Critical patent/JP7752152B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023096692A 2017-11-06 2023-06-13 手術前、手術中または手術後に投与するためのglp-2類似体及びglp-2ペプチボディ Active JP7752152B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762582055P 2017-11-06 2017-11-06
US62/582,055 2017-11-06
JP2020526107A JP7296958B2 (ja) 2017-11-06 2018-11-05 手術前、手術中または手術後に投与するためのglp-2類似体及びglp-2ペプチボディ

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020526107A Division JP7296958B2 (ja) 2017-11-06 2018-11-05 手術前、手術中または手術後に投与するためのglp-2類似体及びglp-2ペプチボディ

Publications (3)

Publication Number Publication Date
JP2023107883A JP2023107883A (ja) 2023-08-03
JP2023107883A5 true JP2023107883A5 (cg-RX-API-DMAC7.html) 2024-03-06
JP7752152B2 JP7752152B2 (ja) 2025-10-09

Family

ID=66332372

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020526107A Active JP7296958B2 (ja) 2017-11-06 2018-11-05 手術前、手術中または手術後に投与するためのglp-2類似体及びglp-2ペプチボディ
JP2023096692A Active JP7752152B2 (ja) 2017-11-06 2023-06-13 手術前、手術中または手術後に投与するためのglp-2類似体及びglp-2ペプチボディ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020526107A Active JP7296958B2 (ja) 2017-11-06 2018-11-05 手術前、手術中または手術後に投与するためのglp-2類似体及びglp-2ペプチボディ

Country Status (14)

Country Link
US (1) US11660328B2 (cg-RX-API-DMAC7.html)
EP (1) EP3706774A4 (cg-RX-API-DMAC7.html)
JP (2) JP7296958B2 (cg-RX-API-DMAC7.html)
KR (1) KR102825098B1 (cg-RX-API-DMAC7.html)
CN (1) CN111629745A (cg-RX-API-DMAC7.html)
AR (1) AR113835A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018360744A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020008936A2 (cg-RX-API-DMAC7.html)
CA (1) CA3079523A1 (cg-RX-API-DMAC7.html)
IL (1) IL274098B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004620A (cg-RX-API-DMAC7.html)
TW (1) TWI911137B (cg-RX-API-DMAC7.html)
WO (1) WO2019090209A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202002080B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018321841A1 (en) * 2017-08-22 2020-02-20 Shire-Nps Pharmaceuticals, Inc. GLP-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
WO2020086741A1 (en) * 2018-10-24 2020-04-30 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
SG11202111312UA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
EP4126003A1 (en) * 2020-03-30 2023-02-08 Zealand Pharma A/S Glp-1/glp-2 dual agonists
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
WO2021263040A1 (en) * 2020-06-26 2021-12-30 Shire-Nps Pharmaceuticals, Inc. Stable peptibody formulations
CN115636876A (zh) * 2021-07-20 2023-01-24 重庆派金生物科技有限公司 胰高血糖素样肽-2突变体的定向化学偶联物及其应用
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用
WO2025181330A1 (en) * 2024-02-29 2025-09-04 Vectivbio Ag Dosage regimens for glucagon-like peptide 2 (glp-2) analogs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1809318T3 (da) * 2004-11-01 2013-09-08 Nps Pharma Inc Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet
JP2009510999A (ja) * 2005-07-29 2009-03-19 エーエムプロテイン コーポレイション キメラ治療剤
AU2006321743A1 (en) * 2005-10-24 2007-06-14 Centocor, Inc. GLP-2 mimetibodies, polypeptides, compositions, methods and uses
US7812121B2 (en) * 2006-08-31 2010-10-12 Baker Audrey E GLP-2 mimetibodies, polypeptides, compositions, methods and uses
JP2008247789A (ja) * 2007-03-30 2008-10-16 Kissei Pharmaceut Co Ltd クローン病に伴う腸管狭窄の進展抑制用医薬組成物
ES2687651T3 (es) * 2011-09-12 2018-10-26 Amunix Operating Inc. Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
US10137170B2 (en) * 2013-12-20 2018-11-27 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도

Similar Documents

Publication Publication Date Title
IL274098B2 (en) Glp-2 analogs and peptibodies for administration before during, or after surgery
Lever Methotrexate and prednisone in pemphigus vulgaris: therapeutic results obtained in 36 patients between 1961 and 1970
Buchwald et al. Ileal bypass in patients with hypercholesterolemia and atherosclerosis: preliminary report on therapeutic potential
JP2021502389A5 (cg-RX-API-DMAC7.html)
Halloun et al. Bariatric surgery in adolescents with obesity: long-term perspectives and potential alternatives
JP2019530648A5 (cg-RX-API-DMAC7.html)
Hermann Acquired Brown's syndrome of inflammatory origin: response to locally injected steroids
Sticherling Systemic sclerosis–the dermatological perspective
Han et al. Management of eosinophilic granuloma occurring in the appendicular skeleton in children
Sharma et al. Primary spinal epidural Ewing's sarcoma
Shah et al. Sinus node dysfunction secondary to hyperparathyroidism
Ozaki et al. Manifestation of latent left ventricular outflow tract obstruction caused by acute myocardial infarction: an important complication of acute myocardial infarction
Hanna et al. Efficacy and complications of intravesical BCG in immunocompromised patients
CN104815090B (zh) 一种治疗闭合性损伤的外用制剂及其制备方法
Katsube et al. Interposition grafting of collagen-gelatin sponge impregnated with basic fibroblast growth factor in primary palatoplasty
Kaddioui et al. Pansclerotic morphea: a historical case in children
Greenberg et al. Current and emerging multiple sclerosis therapeutics
Akhyar et al. Clinical features and evaluation of systemic sclerosis: A dermatology-based case series
Elbrønd et al. Circinoma Linguae: A series of 96 patients
Javier et al. Skeletal recovery from hepatitis C-associated osteosclerosis (HCAO) following antiviral treatment
Dennie et al. A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors
Hendi et al. Advanced age is a strongly benefit for patients undergoing laparoscopic pancreaticodoudenectomy, comparative study
Di Nuzzo et al. Safety of etanercept treatment in psoriatic patients with chronic hepatitis c infection: Preliminary data from a clinical and virological study in five patients
Kądziołka et al. Systemic Sclerosis–A Diagnostic Challenge or a Clinically Controllable Disease?
Hrkač et al. Early cyclophosphamide treatment in new-onset progressive cutaneous systemic sclerosis–a case report and literature review